Clinical Trial

A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide

Name: A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide — clinical trial record (NCT07585747)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CUREMZL002

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Evaluate the efficacy and safety of orelabrutinib, tafasitamab, and lenalidomide in the first-line treatment of patients with follicular lymphoma.

Trial Details

NCT Number	NCT07585747
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Follicular Lymphoma
Enrollment	27 participants
Start Date	2026-04-15
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-14